Abstract
Aim To investigate the association of retinal vascular parameters (calibre, tortuosity, fractal dimension and the number of segments) with incident heart failure (HF) in the UK Biobank.
Methods Participants with fundus images in UK Biobank were included. Retinal vascular parameters were assessed by an artificial intelligence system (RMHAS). Incident HF events were determined by hospital inpatient data, death register records and self-reported medical condition. Cox proportional hazards regression models (CPH) were used to investigate the links between retinal vascular variables and the risk of HF.
Results We included 56470 individuals. After a median of 10.95-year follow-up, 1062 incident HF events were reported. After adjusting for conventional HF risk factors in CPH, we found larger retinal venular calibre (hazard ratio [HR], 1.54; 95% confidence interval [CI], 1.12-2.14), smaller arteriolar fractal dimension (HR, 1.98; 95% CI, 1.38-2.85), smaller venular fractal dimension (HR, 1.52; 95% CI, 1.09-2.13), the smaller number of arteriolar segments (HR, 2.18; 95% CI, 1.47-3.24) and the smaller number of venular segments (HR, 1.85; 95% CI, 1.29-2.64) were linked to an increased risk of HF. The addition of retinal vessel measurements to traditional HF risk factors increased the discrimination capability for predicting future HF, with C statistics changing from 0.799 to 0.813.
Conclusions Wider retinal venular calibre, lower vascular fractal dimension and a smaller number of vessel segments were associated with a higher risk of incident HF events. These results point to the potential application of using early retinal vasculature changes to identify people at higher risk of HF.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Natural Science Foundation of China (81770932 and 82171061).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK Biobank received ethics approval from the North West Research Ethics Committee (reference number 06/MRE08/65). All participants provided informed consent. The study was performed following the principles of the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data from the UK Biobank are available to researchers by application via the UK-Biobank online Access Management System.
Data Availability
Data from the UK Biobank are available to researchers by application via the UK-Biobank online Access Management System.
